Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...

Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

In a report released on January 20, Matthew Hedberg from RBC Capital maintained a Buy rating on ServiceNow (NOW – Research Report), with a ...

RBC Capital analyst Rishi Jaluria maintained a Buy rating on Microsoft (MSFT – Research Report) on January 20 and set a price target of ...

Stocks trading under $10 can be attractive for investors looking to scoop up some cheap shares. Unfortunately, quality stocks ...

The latest Apple stock downgrade centers around iPhone sales and the weakening consumer electronics market. Here's what ...

Bank of America analyst Lorraine Hutchinson reiterated a Buy rating on Bath & Body Works and maintained its $45 price target.

UBS Maintains Buy on Netflix, Raises Price Target to $1150 Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings ...

If you have an extra $1,000 sitting in a savings or checking account, one of the best ways to earn a return on that money is ...

FinVolution's international expansion and low delinquency rates drive growth. See why FINV stock is a Strong Buy with a strong balance sheet and dividends.